Presented by Silke Geirnaert (University Hospital, Ghent, Belgium)
Chronic obstructive pulmonary disease (COPD) is characterized by persistent inflammation and emphysematous destruction of lung tissue, in which cell death plays a central role. In this respect, ferroptosis, an iron-dependent necrotic form of cell death driven by lipid peroxidation, may represent a key pathogenic mechanism in COPD.
Using human lung samples Silke Geirnaert, PhD student at the Ghent University Hospital, assessed specific ferroptosis markers such as glutathione peroxidase-4 (GPX4) and lipid peroxidation. With both these markers significant increases were seen across healthy never-smokers, smokers, and COPD patients, suggesting a progressive role of ferroptosis in disease development.
They subsequently investigated whether ferroptosis inhibition could mitigate experimental COPD phenotypes. In acute models, daily administration of the ferroptosis inhibitor UAMC-3203 during five days of cigarette smoke exposure in C57BL/6 mice significantly reduced bronchoalveolar lavage (BAL) macrophages and the total number of BAL cells. Similarly, in a one-week elastase-induced emphysema model, inhibitor treatment reduced emphysema severity.
In a four-week smoke-exposure model, dose-dependent effects were observed, with higher inhibitor doses progressively reducing the number of neutrophils and dendritic cells. Gene expression analyses confirmed beneficial effects, with significant reductions in MMP-12 and CXCL-1, and upregulation of GPX4.
These findings demonstrate that ferroptosis contributes to both inflammation and tissue destruction in COPD. As such, inhibition of ferroptosis may represent a promising therapeutic strategy in this disease entity.
References:
Geirnaert S, et al. ERS2025; Abstract 2606